Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.43 |
| ▸ | DRD2 | P14416 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | DRD3 | P35462 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330325 | 0.80 | SCN9A (0.34) | SCN9APKMEPHX2 | |
| SCHEMBL3333536 | 0.79 | SCN9A (0.55) | SCN9A | |
| SCHEMBL3330324 | 0.73 | SCN9A (0.36) | SCN9AALDH1A1MAPTPKMHTT | |
| SCHEMBL14221668 | 0.69 | SCN9A (0.43) | SCN9ALMNAPOLBEPHX2 | |
| SCHEMBL14221705 | 0.65 | SCN9A (0.42) | SCN9ALMNAPOLB | |
| SCHEMBL3330443 | 0.65 | SCN9A (0.46) | SCN9ALMNAALDH1A1MAPT | |
| SCHEMBL484184 | 0.65 | SCN9A (0.42) | SCN9AALDH1A1 | |
| SCHEMBL3335377 | 0.65 | SCN9A (0.40) | SCN9ALMNAALDH1A1 | |
| SCHEMBL3334296 | 0.65 | SCN9A (0.54) | SCN9A | |
| SCHEMBL14221187 | 0.64 | SCN9A (0.44) | SCN9ALMNAPOLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885DRD2 612/4885HTR2A 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.